Silence Therapeutics PLC (SLN) - Total Liabilities
Based on the latest financial reports, Silence Therapeutics PLC (SLN) has total liabilities worth $72.73 Million USD as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore net asset momentum of Silence Therapeutics PLC to track the company's year-over-year net asset growth rate.
Silence Therapeutics PLC - Total Liabilities Trend (1995–2024)
This chart illustrates how Silence Therapeutics PLC's total liabilities have evolved over time, based on quarterly financial data. See how much free cash does Silence Therapeutics PLC generate to measure how efficiently the company converts operating cash flow to free cash.
Silence Therapeutics PLC Competitors by Total Liabilities
The table below lists competitors of Silence Therapeutics PLC ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Guangdong New Grand Long Packing Co Ltd
SHE:002836
|
China | CN¥164.48 Million |
|
Lime Technologies AB (publ)
ST:LIME
|
Sweden | Skr556.23 Million |
|
Taeyoung Engineering & Construction Co.,Ltd.
KO:009410
|
Korea | ₩3.15 Trillion |
|
Tyro Payments Ltd
AU:TYR
|
Australia | AU$320.74 Million |
|
Shanghai No1 Pharmacy Co Ltd
SHG:600833
|
China | CN¥799.41 Million |
|
Pinlive Foods Co Ltd
SHE:300892
|
China | CN¥241.21 Million |
|
VT GMP Co.Ltd
KQ:018290
|
Korea | ₩93.15 Billion |
|
Yunnan Metropolitan Real Estate Development Co Ltd
SHG:600239
|
China | CN¥7.82 Billion |
Liability Composition Analysis (1995–2024)
This chart breaks down Silence Therapeutics PLC's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Silence Therapeutics PLC stock valuation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 7.69 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.98 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.50 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Silence Therapeutics PLC's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Silence Therapeutics PLC (1995–2024)
The table below shows the annual total liabilities of Silence Therapeutics PLC from 1995 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $68.61 Million | -29.60% |
| 2023-12-31 | $97.45 Million | +14.08% |
| 2022-12-31 | $85.43 Million | -2.56% |
| 2021-12-31 | $87.67 Million | +13.98% |
| 2020-12-31 | $76.91 Million | +205.59% |
| 2019-12-31 | $25.17 Million | +557.13% |
| 2018-12-31 | $3.83 Million | +44.15% |
| 2017-12-31 | $2.66 Million | +65.03% |
| 2016-12-31 | $1.61 Million | +44.01% |
| 2015-12-31 | $1.12 Million | -44.46% |
| 2014-12-31 | $2.01 Million | +16.76% |
| 2013-12-31 | $1.72 Million | +79.77% |
| 2012-12-31 | $959.00K | -23.89% |
| 2011-12-31 | $1.26 Million | -25.27% |
| 2010-12-31 | $1.69 Million | -19.83% |
| 2009-12-31 | $2.10 Million | +124.92% |
| 2008-12-31 | $935.00K | -48.11% |
| 2007-12-31 | $1.80 Million | +72.61% |
| 2006-12-31 | $1.04 Million | -29.70% |
| 2005-12-31 | $1.49 Million | +75.53% |
| 2004-12-31 | $846.00K | -35.22% |
| 2003-12-31 | $1.31 Million | +27.04% |
| 2002-12-31 | $1.03 Million | +41.79% |
| 2001-12-31 | $725.00K | -24.79% |
| 2000-12-31 | $964.00K | -39.86% |
| 1999-12-31 | $1.60 Million | +165.84% |
| 1998-12-31 | $603.00K | -5.78% |
| 1997-12-31 | $640.00K | +53.48% |
| 1996-12-31 | $417.00K | +38.54% |
| 1995-12-31 | $301.00K | -- |
About Silence Therapeutics PLC
Silence Therapeutics plc, a biotechnology company, engages in the discovery and development of novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company develops Zerlasiran (SLN360), which is in Phase II clinical trial for cardiovascular disease associated with elevated … Read more